Egypt to provide EGP 90bn in financing facilities for key sectors at interest rates below 15% this fiscal year    Fragile Gaza ceasefire tested as humanitarian crisis deepens    Egypt explores cooperation with Chinese firms to advance robotic surgery    Avrio Gold to launch new jewellery, bullion factory in early 2026    Egypt approves Temsah offshore concession reassignment to EGPC, Ieoc, BP    CBE, China's National Financial Regulatory sign MoU to strengthen joint cooperation    AUC makes history as 1st global host of IMMAA 2025    Al Ismaelia launches award-winning 'TamaraHaus' in Downtown Cairo revival    Al-Sisi, Burhan discuss efforts to end Sudan war, address Nile Dam dispute in Cairo talks    Egypt's Sisi, Sudan's Al-Burhan renew opposition to Ethiopia's unilateral Blue Nile moves    Egyptian pound edges up slightly against US dollar in early Wednesday trade    Egypt starts October Takaful and Karama payments worth over EGP 4b to 4.7m families    Egypt's Cabinet hails Sharm El-Sheikh peace summit as turning point for Middle East peace    Gaza's fragile ceasefire tested as aid, reconstruction struggle to gain ground    Egypt's human rights committee reviews national strategy, UNHRC membership bid    Trump-Xi meeting still on track    Al-Sisi, world leaders meet in Sharm El-Sheikh to coordinate Gaza ceasefire implementation    Egypt's Sisi warns against unilateral Nile actions, calls for global water cooperation    Egypt unearths one of largest New Kingdom Fortresses in North Sinai    Egypt unearths New Kingdom military fortress on Horus's Way in Sinai    Egypt Writes Calm Anew: How Cairo Engineered the Ceasefire in Gaza    Egypt's acting environment minister heads to Abu Dhabi for IUCN Global Nature Summit    Egyptian Open Amateur Golf Championship 2025 to see record participation    Cairo's Al-Fustat Hills Park nears completion as Middle East's largest green hub – PM    Egypt's Cabinet approves decree featuring Queen Margaret, Edinburgh Napier campuses    El-Sisi boosts teachers' pay, pushes for AI, digital learning overhaul in Egypt's schools    Egypt's Sisi congratulates Khaled El-Enany on landslide UNESCO director-general election win    Syria releases preliminary results of first post-Assad parliament vote    Karnak's hidden origins: Study reveals Egypt's great temple rose from ancient Nile island    Egypt resolves dispute between top African sports bodies ahead of 2027 African Games    Egypt reviews Nile water inflows as minister warns of impact of encroachments on Rosetta Branch    Egypt's ministry of housing hails Arab Contractors for 5 ENR global project awards    Egypt aims to reclaim global golf standing with new major tournaments: Omar Hisham    Egypt to host men's, juniors' and ladies' open golf championships in October    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



With Wuhan virus genetic code in hand, scientists begin work on a vaccine
Published in Ahram Online on 26 - 01 - 2020

When a newly organized vaccine research group at the U.S. National Institutes of Health (NIH) met for the first time this week, its members had expected to be able to ease into their work. But their mandate is to conduct human trials for emerging health threats - and their first assignment came at shocking speed.
In just three months time, they likely will be testing the first of a number of potential experimental vaccines against the new SARS-like coronavirus that is spreading in China and beyond.
“I told them, ‘you are going to have your baptism of fire, folks',” Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases within NIH, said of his inaugural address to the group this week.
Three months from gene sequence to initial human testing would be the fastest the agency has ever gotten such a vaccine off the ground, Fauci said.
The outbreak, which began in the central Chinese city of Wuhan in December, as of Friday had infected more than 800 people in China and killed 26. Cases have also been confirmed in Thailand, Vietnam, Singapore, Japan, South Korea, Taiwan, Nepal and the United States.
Chinese scientists were able to quickly identify the genetic sequence of the new coronavirus and officials posted it publicly within a few days, allowing scientific research teams to get to work right away.
With the genetic code in hand, scientists can start vaccine development work without needing a sample of the virus.
During the deadly 2003 Severe Acute Respiratory Syndrome (SARS) outbreak, it took U.S. scientists 20 months to go from genetic sequence to the first phase of human trials. By that time, the outbreak was under control.
This time, research groups worldwide are already executing plans to test vaccines, treatments and other countermeasures to stop the newly identified virus from spreading globally.
Multi-pronged approach
They are attacking from several angles, with global health and epidemic response agencies hoping at least one treatment will be in human trials within a few months.
Fauci's agency is partnering with U.S. biotech Moderna Inc, which specializes in vaccines based on ribonucleic acid (RNA) - a chemical messenger that contains instructions for making proteins.
That team hopes to make an RNA vaccine based on one of the crown-like spikes on the surface of the coronavirus that gives the family of viruses their name, an approach that, unlike many vaccines, would not expose people to the virus.
At the University of Queensland in Australia, scientists backed by the global health emergency group the Coalition for Epidemic Preparedness Innovations (CEPI) said they are working on what they describe as a “molecular clamp” vaccine approach.
The technology adds a gene to viral proteins to stabilize them and trick the body into thinking it is seeing a live virus and create antibodies against it.
Keith Chappell, an expert in the University's school of chemistry and molecular biosciences, said the technology is designed as “a platform approach to generate vaccines against a range of human and animal viruses.”
It has already shown promising results in lab tests on other dangerous viruses such as Ebola and the coronavirus that causes Middle East Respiratory Syndrome (MERS)- a cousin of SARS and the Wuhan virus.
Novavax, which already has a vaccine in development against MERS, says it is now working on one for the Wuhan coronavirus.
Scientists also are turning to infection-fighting proteins known as monoclonal antibodies, or mAbs, that were developed against the SARS and MERS coronaviruses.
The hope is that similarities with the Wuhan virus will offer enough overlap in the antibodies to help people infected in the China outbreak.
Vir Biotechnology Chief Scientific Officer Herbert Virgin said his company has a library of monoclonal antibodies that have shown some success against SARS and MERS in lab tests.
Some of these antibodies have been shown to neutralize coronaviruses, Virgin said, and “may have the potential to treat and prevent (the) Wuhan coronavirus.”


Clic here to read the story from its source.